Clinical Trial: Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access

Official Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options

Brief Summary: The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Detailed Summary:
Sponsor: Gilead Sciences

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Gilead Sciences

Dates:
Date Received: July 9, 2007
Date Started:
Date Completion:
Last Updated: July 29, 2011
Last Verified: July 2011